Amarin Corp Plc (AMRN)

[Sam81]

Jefferies Upside Scenario: PT $18

Upside Scenario
- De-risked Vascepa program in mixed dyslipidemia through positive REDUCE-IT data, leading to approval in this patient population
- Potential for REDUCE-IT to stop early for efficacy on second interim analysis expected in ~mid-2017
- Worldwide partnership
- DCF-based PT: $18.00

Downside Scenario
- REDUCE-IT runs to completion with negative results
- AMRN does not partner or successfully develop Vascepa ex-U.S.
- DCF-based PT (based on MARINE population alone): $0.50

I would take such risk at any day 85% downside compared to 456% upside
(personally: it's exactly 70.05% downside with regard to my average)

Long & Strong !!